Clinical Trial Search

Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants

Primary: Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate — 54 Participants

Primary: Rate of Participants Who Were Alive at 2 Years — 71; 53 percentage of participants

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Evaluation of Safety and Toxicity — 1; 1; 1; 1 participants

Primary: Pathological Complete Response — 26 participants

Primary: Number of Participants With Pathologic Complete Response Following Surgery — 18 participants

Primary: Pathologic Complete Response (PCR) Rate

Primary: Complete Pathologic Response (pCR) — 36.6 percentage of participants

Primary: Percentage of Participants With Pathologic Complete Response (PCR) — 28.6; 40.7 percentage of participants

Primary: Number of Participants With Overall Response Rate (RR) — 44 participants

Primary: Number of Participants With Pathologic Complete Response (pCR) — 11 Participants

Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants

Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants

Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants

Primary: Pathologic Complete Response — 55 participants

Primary: Pathologic Complete Response (pCR) Rate — 18 Participants

Primary: Complete Pathologic Response Rate — 14 percentage of participants

Primary: Histological Response Determined by FDG Uptake Correlates — 2; 3; 38 participants

Primary: Pathologic Complete Response Rate — 13; 26 percentage of participants

Primary: Disease-free Survival — 4 Participants

Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery — 24 Participants

Primary: Overall Survival (24-month Rate Reported) — 44.9; 44.0 percentage of participants — p=0.47

Primary: Overall Response Rate — 0.029 proportion of paticipants

Primary: Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments — 4.4; 5.6 months — p=0.3158

Primary: Progression-free Survival (PFS) in High-ERCC1 Patients — 4.7; 5.3 months — p=0.83

Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants

Primary: Overall Survival — 13.4 month

Primary: Number of Participants With Dose Limiting Toxicity — 0 Participants

Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098